Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose This study aimed to develop a nomogram for predicting pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) by integrating hematological biomarkers and clinicopathological characteristics. Materials and Methods Between 2003 and 2017, 306 ESCC patients who underwent neoadjuvant CRT followed by esophagectomy were analyzed. Besides clinicopathological factors, hematological parameters before, during, and after CRT were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR. A nomogram model was built and internally validated. Results Absolute lymphocyte count (ALC), lymphocyte to monocyte ratio, albumin, hemoglobin, white blood cell, neutrophil, and platelet count generally declined, whereas neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) increased significantly following neoadjuvant CRT. After surgery, 124 patients (40.5%) achieved a pCR. The pCR group demonstrated significantly more favorable survival than the non-pCR group. On multivariate analysis, significant factors associated with pCR included sex, chemotherapy regimen, post-CRT endoscopic finding, pre-CRT NLR, ALC nadir during CRT, and post-CRT PLR, which were incorporated into the prediction model. The nomogram indicated good accuracy in predicting pCR, with a C-index of 0.75 (95% confidence interval, 0.71 to 0.78). Conclusion Female, chemotherapy regimen of cisplatin/vinorelbine, negative post-CRT endoscopic finding, pre-CRT NLR (≤ 2.1), ALC nadir during CRT (> 0.35×109/L), and post-CRT PLR (≤ 83.0) were significantly associated with pCR in ESCC patients treated with neoadjuvant CRT. A nomogram incorporating hematological biomarkers to predict pCR was developed and internally validated, showing good predictive performance.
Abstract
Purpose This study aimed to develop a nomogram for predicting pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) by integrating hematological biomarkers and clinicopathological characteristics. Materials and Methods Between 2003 and 2017, 306 ESCC patients who underwent neoadjuvant CRT followed by esophagectomy were analyzed. Besides clinicopathological factors, hematological parameters before, during, and after CRT were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR. A nomogram model was built and internally validated. Results Absolute lymphocyte count (ALC), lymphocyte to monocyte ratio, albumin, hemoglobin, white blood cell, neutrophil, and platelet count generally declined, whereas neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) increased significantly following neoadjuvant CRT. After surgery, 124 patients (40.5%) achieved a pCR. The pCR group demonstrated significantly more favorable survival than the non-pCR group. On multivariate analysis, significant factors associated with pCR included sex, chemotherapy regimen, post-CRT endoscopic finding, pre-CRT NLR, ALC nadir during CRT, and post-CRT PLR, which were incorporated into the prediction model. The nomogram indicated good accuracy in predicting pCR, with a C-index of 0.75 (95% confidence interval, 0.71 to 0.78). Conclusion Female, chemotherapy regimen of cisplatin/vinorelbine, negative post-CRT endoscopic finding, pre-CRT NLR (≤ 2.1), ALC nadir during CRT (> 0.35×109/L), and post-CRT PLR (≤ 83.0) were significantly associated with pCR in ESCC patients treated with neoadjuvant CRT. A nomogram incorporating hematological biomarkers to predict pCR was developed and internally validated, showing good predictive performance.
참고문헌 (33)
- Sjoquist KM, "Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma : an updated meta-analysis", Lancet Oncol, 12, pp.681~692 (2011)
- van Hagen P, "Preoperative chemoradiotherapy for esophageal or junctional cancer", N Engl J Med, 366, pp.2074~2084 (2012)
- Shapiro J, "Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS) : long-term results of a randomised controlled trial", Lancet Oncol, 16, pp.1090~1098 (2015)
- Yang H, "Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus(NEOCRTEC5010) : a phase III multicenter, randomized, open-label clinical trial", J Clin Oncol, 36, pp.2796~2803 (2018)
- Mariette C, "Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer : final analysis of randomized controlled phase III trial FFCD 9901", J Clin Oncol, 32, pp.2416~2422 (2014)
- Scheer RV, "Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer", Int J Radiat Oncol Biol Phys, 80, pp.996~1001 (2011)
- van der Wilk BJ, "Towards an organ-sparing approach for locally advanced esophageal cancer", Dig Surg, 36, pp.462~469 (2019)
- Xi M, "Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer : impact of histology on recurrence patterns and outcomes", Ann Surg, 269, pp.663~670 (2019)
- Grivennikov SI, "Immunity, inflammation, and cancer", Cell, 140, pp.883~899 (2010)
- Davuluri R, "Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy", Int J Radiat Oncol Biol Phys, 99, pp.128~135 (2017)
- Shiraishi Y, "Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer : a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy", Radiother Oncol, 128, pp.154~160 (2018)
- Zhou XL, "Lymphopenia in esophageal squamous cell carcinoma : relationship to malnutrition, various disease parameters, and response to concurrent chemoradiotherapy", Oncologist, 24, pp.e677~86 (2019)
- Fang P, "High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer", Radiother Oncol, 128, pp.584~590 (2018)
- Li Q, "Treatmentrelated lymphopenia predicts pathologic complete response and recurrence in esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy", Ann Surg Oncol, 26, pp.2882~2889 (2019)
- Suzuki R, "Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer", Radiother Oncol, 126, pp.499~505 (2018)
- Xie D, "Nomograms predict overall survival for patients with smallcell lung cancer incorporating pretreatment peripheral blood markers", J Thorac Oncol, 10, pp.1213~1220 (2015)
- Ishibashi Y, "Prognostic value of preoperative systemic immunoinflammatory measures in patients with esophageal cancer", Ann Surg Oncol, 25, pp.3288~3299 (2018)
- Hirahara N, "Prognostic significance of preoperative inflammatory response biomarkers in patients undergoing curative thoracoscopic esophagectomy for esophageal squamous cell carcinoma", Eur J Surg Oncol, 43, pp.493~501 (2017)
- 허재성, "Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer", Cancer Research and Treatment, 48(1), pp.232~239 (2016), 대한암학회[DOI]
- Deng W, "The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy", Radiother Oncol, 133, pp.9~15 (2019)
- Mantovani A, "Cancer-related inflammation", Nature, 454, pp.436~444 (2008)
- McLaren PJ, "Neutrophil-to-lymphocyte and plateletto-lymphocyte ratios can predict treatment response to neoadjuvant therapy in esophageal cancer", J Gastrointest Surg, 21, pp.607~613 (2017)
- Tustumi F, "The value of cellular components of blood in the setting of trimodal therapy for esophageal cancer", J Surg Oncol, 121, pp.784~794 (2020)
- Conroy T, "Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group", J Clin Oncol, 14, pp.164~170 (1996)
- Liu SL, "Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma : a matched case-control study", Radiother Oncol, 116, pp.262~268 (2015)
- Ajani JA, "Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer", Ann Oncol, 23, pp.2638~2642 (2012)
- Toxopeus EL, "Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer", Radiother Oncol, 115, pp.392~398 (2015)
- Chao YK, "Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma", Dis Esophagus, 30, pp.1~8 (2017)
- Noordman BJ, "Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer(preSANO) : a prospective multicentre, diagnostic cohort study", Lancet Oncol, 19, pp.965~974 (2018)
- Borggreve AS, "Preoperative prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal cancer using(18)F-FDG PET", CT and DW-MRI : a prospective multicenter study, 2020, pp.106, 998~1009
- Beukinga RJ, "Prediction of response to neoadjuvant chemotherapy and radiation therapy with baseline and restaging(18)F-FDG PET imaging biomarkers in patients with esophageal cancer", Radiology, 287, pp.983~992 (2018)
- Azad TD, "Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer", Gastroenterology, 158, pp.494~505 (2020)
- Zhou S, "Indoleamine 2, 3-dioxygenase 1 and programmed cell death-ligand 1co-expression predicts poor pathologic response and recurrence in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy", Cancers(Basel), 11, pp.169~ (2019)